The Role of Bioanalytical Solutions in Clinical Trials

Bioanalytical solutions such as qPCR assays are critical in drug discovery and development. The data derived from such bioanalytical services are vital for defining the characteristics of a potential drug molecule. Besides, bioanalytical laboratory services help scientists identify potential treatment areas where such drug molecules can be the most effective. Additionally, bioanalytical solutions are necessary for regulatory filings. This additional need drives the requirement for outsourcing partners with in-depth expertise in developing and conducting experiments and experience in handling regulatory requirements. The current article focuses on bioanalytical laboratory solutions during clinical trials. 

Bioanalytical services in clinical trials

Bioanalytical solutions designed to detect and estimate drug concentrations in clinical studies are vital for different clinical pharmacological aspects such as bioavailability, bioequivalence, toxicokinetics, and pharmacokinetic evaluations. So, Bioanalytical solutions support studies and help in the decision-making process for drug safety, labeling, and approval. Hence, therapeutic products without adequate bioanalytical data will not be approved. 

Additionally, the scientific data acquired from bioanalytical assays goes beyond the regulatory requirements of conducting biological studies. Data gathered from safety and efficacy studies in animal models help researchers determine the half-life exposure and other pharmacological properties and identify proper doses for subsequent clinical studies.

Bioanalytical solutions go beyond simple drug measurements over time. They assess the efficacy of a product through pharmacodynamic endpoints. Bioanalytical studies can help researchers understand early efficacy data and safety concerns. Besides, they can help stratify patients as responders or nonresponders. Notably, immunogenicity testing is a crucial aspect of bioanalytical solutions during clinical trials. A positive immunogenicity result may be beneficial for vaccine development. However, they may quickly become unwanted in other biotherapeutic developments as unwanted immunogenicity may influence the safety, efficacy, and pharmacokinetic profile of drug products. 

Method development is often a black box to several sponsors. It requires an in-depth understanding of the drug product and intense training. Biological studies involve highly complex and undefined biological samples with interference from millions of compounds. The required expertise and knowledge to perform successful bioanalytical studies may not be available in-house, especially with ever-evolving regulatory requirements. Besides, most bioanalytical studies are now focused on mass spectrometry-based analysis, which requires expensive and specialized instrumentation. Moreover, clinical studies are highly regulated. Therefore, sponsors are increasingly relying on outsourcing partners with expertise in bioanalysis and established quality systems and requirements to fulfill all regulatory requirements. 

Moreover, partnering with bioanalytical laboratory services can be extremely helpful for multiple reasons. Often, small-size companies exceed their current capacities and may require an outsourcing partner to complete the necessary experiments. Besides, labs may lack experience or equipment and contract another laboratory for the same services. Bioanalytical laboratory services are particularly useful for smaller startups as they can offer valuable consulting services and be a one-stop solution for all bioanalytical needs. Contract laboratories have a deep understanding of clinical studies and experience in handling a diverse range of bioanalytical assays. Most importantly, as they are exposed to a wide range of clinical projects, they are frequently audited by regulatory agencies and have a comprehensive understanding of regulatory practices.